{"id":787199,"date":"2023-09-29T17:44:57","date_gmt":"2023-09-29T21:44:57","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/immunogen-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-31\/"},"modified":"2023-09-29T17:44:57","modified_gmt":"2023-09-29T21:44:57","slug":"immunogen-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-31","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/immunogen-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-31\/","title":{"rendered":"ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"},"content":{"rendered":"<p>        <!--body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p><b>ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)<\/b><\/p>\n<p>WALTHAM, Mass.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the compensation committee of the Company\u2019s Board of Directors (the \u201cCompensation Committee\u201d) approved, effective as of September 25, 2023, grants of non-qualified stock options to purchase 258,300 shares of its common stock (the \u201cSeptember 25<sup>th<\/sup> Options\u201d) and restricted stock units (\u201cRSUs\u201d) covering 43,050 shares of its common stock under the Inducement Plan to a new employee. Also, effective September 29, 2023, the Compensation Committee approved grants of non-qualified stock options to purchase an aggregate of 297,355 shares of its common stock (the \u201cSeptember 29<sup>th<\/sup> Options\u201d) and RSUs covering an aggregate of 55,268 shares of its common stock under the Inducement Plan to six new employees.<\/p>\n<p>\nThe Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of ImmunoGen (or following a bona fide period of non-employment), as an inducement material to such individual\u2019s entering into employment with ImmunoGen, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.<\/p>\n<p>\nThe September 25<sup>th<\/sup> Options and the September 29<sup>th<\/sup> Options have exercise prices of $14.63 and $15.87 per share, which is equal to the closing price of ImmunoGen\u2019s common stock on the Nasdaq Global Select Market on September 25, 2023 and September 29, 2023, respectively. Each option granted under the September 25<sup>th<\/sup> Options and the September 29<sup>th<\/sup> Options will vest as to 25% of the shares underlying such option on the first anniversary of the grant date and as to an additional 6.25% of the shares underlying the option quarterly thereafter, subject to each employee\u2019s continued employment on each vesting date. Each RSU under all grants will vest as to 25% of the shares underlying the RSU award on the first anniversary of the grant date and as to an additional 25% of the shares underlying the RSU award annually thereafter, subject to each employee\u2019s continued employment on each vesting date. Each option under the September 25<sup>th<\/sup> Options and the September 29<sup>th<\/sup> Options and each RSU under all grants is subject to the terms and conditions of the Inducement Plan and the terms and conditions of a stock option agreement and an RSU agreement covering the respective grants.<\/p>\n<p><b>ABOUT IMMUNOGEN<\/b><\/p>\n<p>\nImmunoGen is developing the next generation of antibody-drug conjugates to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW\u2122.<\/p>\n<p>\nLearn more about who we are, what we do, and how we do it at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.immunogen.com&amp;esheet=53566081&amp;newsitemid=20230928192083&amp;lan=en-US&amp;anchor=www.immunogen.com&amp;index=1&amp;md5=f3b6e4ba95950f7ab59743291f8d4503\">www.immunogen.com<\/a>.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230928192083r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20230928192083\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20230928192083\/en\/<\/a><\/span><\/p>\n<p><b>INVESTOR RELATIONS CONTACT<br \/>\n<\/b><br \/>ImmunoGen<br \/>\n<br \/>Anabel Chan<br \/>\n<br \/>781-895-0600<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:anabel.chan@immunogen.com\">anabel.chan@immunogen.com<\/a><\/p>\n<p><b>MEDIA CONTACTS<br \/>\n<\/b><br \/>ImmunoGen<br \/>\n<br \/>Courtney O\u2019Konek<br \/>\n<br \/>781-895-0600<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:courtney.okonek@immunogen.com\">courtney.okonek@immunogen.com<\/a><\/p>\n<p>\nOR<\/p>\n<p>\nFTI Consulting<br \/>\n<br \/>Robert Stanislaro<br \/>\n<br \/>212-850-5657<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:robert.stanislaro@fticonsulting.com\">robert.stanislaro@fticonsulting.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Massachusetts United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Oncology Health Research Pharmaceutical Science Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230928192083\/en\/1902420\/3\/imgnlogo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WALTHAM, Mass.&#8211;(BUSINESS WIRE)&#8211; ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the compensation committee of the Company\u2019s Board of Directors (the \u201cCompensation Committee\u201d) approved, effective as of September 25, 2023, grants of non-qualified stock options to purchase 258,300 shares of its common stock (the \u201cSeptember 25th Options\u201d) and restricted stock units (\u201cRSUs\u201d) covering 43,050 shares of its common stock under the Inducement Plan to a new employee. Also, effective September 29, 2023, the Compensation Committee approved grants of non-qualified stock options to purchase an aggregate of 297,355 shares of its common stock (the \u201cSeptember 29th Options\u201d) and &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunogen-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-31\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-787199","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunogen-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-31\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WALTHAM, Mass.&#8211;(BUSINESS WIRE)&#8211; ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the compensation committee of the Company\u2019s Board of Directors (the \u201cCompensation Committee\u201d) approved, effective as of September 25, 2023, grants of non-qualified stock options to purchase 258,300 shares of its common stock (the \u201cSeptember 25th Options\u201d) and restricted stock units (\u201cRSUs\u201d) covering 43,050 shares of its common stock under the Inducement Plan to a new employee. Also, effective September 29, 2023, the Compensation Committee approved grants of non-qualified stock options to purchase an aggregate of 297,355 shares of its common stock (the \u201cSeptember 29th Options\u201d) and &hellip; Continue reading &quot;ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunogen-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-31\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-29T21:44:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230928192083r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunogen-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-31\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunogen-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-31\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\",\"datePublished\":\"2023-09-29T21:44:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunogen-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-31\\\/\"},\"wordCount\":521,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunogen-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-31\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230928192083r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunogen-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-31\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunogen-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-31\\\/\",\"name\":\"ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunogen-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-31\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunogen-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-31\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230928192083r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2023-09-29T21:44:57+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunogen-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-31\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunogen-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-31\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunogen-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-31\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230928192083r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230928192083r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunogen-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-31\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/immunogen-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-31\/","og_locale":"en_US","og_type":"article","og_title":"ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","og_description":"ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WALTHAM, Mass.&#8211;(BUSINESS WIRE)&#8211; ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the compensation committee of the Company\u2019s Board of Directors (the \u201cCompensation Committee\u201d) approved, effective as of September 25, 2023, grants of non-qualified stock options to purchase 258,300 shares of its common stock (the \u201cSeptember 25th Options\u201d) and restricted stock units (\u201cRSUs\u201d) covering 43,050 shares of its common stock under the Inducement Plan to a new employee. Also, effective September 29, 2023, the Compensation Committee approved grants of non-qualified stock options to purchase an aggregate of 297,355 shares of its common stock (the \u201cSeptember 29th Options\u201d) and &hellip; Continue reading \"ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/immunogen-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-31\/","og_site_name":"Market Newsdesk","article_published_time":"2023-09-29T21:44:57+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230928192083r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunogen-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-31\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunogen-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-31\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","datePublished":"2023-09-29T21:44:57+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunogen-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-31\/"},"wordCount":521,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunogen-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-31\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230928192083r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunogen-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-31\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/immunogen-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-31\/","name":"ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunogen-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-31\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunogen-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-31\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230928192083r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2023-09-29T21:44:57+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunogen-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-31\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/immunogen-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-31\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunogen-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-31\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230928192083r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230928192083r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunogen-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-31\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/787199","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=787199"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/787199\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=787199"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=787199"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=787199"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}